ASCO GU Research to Watch: Kidney Cancer

By Karine Tawagi, MD, Samantha Armstrong, MD - Last Updated: February 10, 2025

Drs. Karine Tawagi and Samantha Armstrong, known together as “The Two Onc Docs,” share their thoughts on the research to keep an eye on at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium related to kidney cancer.

Among the mentioned research are COSMIC-313, CheckMate 9ER, KEYMAKER-U03, and more.

Post Tags:ASCO GU Symposium 2025: Focus on Renal Cell Carcinoma

The Journey to a Personalized Vaccine: Dr. David Braun on Neoantigen mRNA Therapy in RCC

David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 24, 2025

Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.

Impact of Insurance Status on Survival Outcomes in Metastatic RCC

Emily MenendezAdvanced Renal Cell Carcinoma | March 19, 2025

Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.

PSMA-Guided MDT Shows Promise in Oligometastatic RCC

Emily MenendezRenal Cell Carcinoma Diagnostics | March 4, 2025

A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.

Expanding Treatment Horizons: Novel Approaches in RCC and Non-Clear Cell Disease

Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025

The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.

Multidisciplinary Approaches to Managing IRAEs in RCC

Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025

The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.

ASCO GU Research to Watch: Kidney Cancer

Related Posts